Triple Combination DAAs for Treating HCV GT1b Subjects
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
There is only one kind of treatment (simeprevir 150 mg + sofosbuvir 400 mg+daclatasvir 60 mg)
in this study but the treatment duration may be different depending on patients' response to
the antiviral therapy and whether patients have liver cirrhosis. If patients have no
cirrhosis and the HCV viral load on day 2 is <500 IU/ml, patients will receive sofosbuvir,
daclatasvir and simeprevir for 3 weeks, otherwise the treatment duration is 4 weeks. If
patients have cirrhosis and the HCV viral load on day 2 is <500 IU/ml, patients will receive
sofosbuvir, daclatasvir and simeprevir for 6 weeks, otherwise the treatment duration will be
8 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Humanity & Healthy GI and Liver Centre Humanity and Health Research Centre
Collaborators:
Beijing 302 Hospital Emory University University of Maryland University of Maryland, College Park